Your sleeping pill may still be driving with you the next morning

Millions of people take medication to sleep and then drive to work hours later. Sedatives that linger in the body can blunt lane control and alertness long after the alarm goes off, which makes residual drug effects a road-safety question as much as a pharmacology one. Individual hypnotics have been put through driving studies for years, but a comparison across the whole class, on the same yardstick, was missing. A network analysis allows every drug and dose to be ranked against placebo and against each other simultaneously.

The researchers searched PubMed, EMBASE, TRID, trial registries and Web of Science for randomised controlled trials of hypnotics that measured driving, up to late May 2023. From 4,805 records, 26 trials entered the systematic review and 22 fed the network analysis, which focused on healthy subjects. The key outcome was the standard deviation of lateral position, essentially how much a driver weaves within a lane, assessed on the first morning after dosing and at endpoint. Rates of driving impairment, risk of bias and confidence in the evidence were also examined.

After a single dose, most molecules matched placebo on weaving and outperformed zopiclone. Several did worse than placebo: ramelteon 8 mg, daridorexant 100 mg, zolpidem 10 mg at bedtime, zolpidem 10 mg and 20 mg taken in the middle of the night, mirtazapine 15 to 30 mg, and triazolam 0.5 mg. Lemborexant 2.5 to 5 mg, suvorexant 15 to 20 mg and middle-of-the-night zolpidem 3.5 mg were associated with less impairment than zopiclone. Repeated dosing, followed for up to ten days, produced fewer residual effects than single doses, with flurazepam the exception.

The analysis supports the long-standing view of zopiclone as a benchmark next-morning impairer and suggests most FDA-approved hypnotics at in-label doses overlap with placebo on driving. It complicates the picture for specific drugs and doses, including some newer agents, which underperformed placebo after a single dose. The largest limitation is that the authors themselves rated confidence in the evidence low or very low, and the network rested on healthy volunteers, whose responses may differ from people with insomnia. Whether residual effects keep fading with use beyond 15 days remains an open question the authors flag for further research.

If a sleep medication is part of your routine and so is a morning drive, this is a reason to know that drugs in this class are not interchangeable on next-day performance. Dose and timing mattered in these tests, middle-of-the-night dosing of some drugs looked worse, and repeated use appeared to soften residual effects for most drugs. Given the low confidence ratings, the sensible reading is as material for a conversation with a prescriber rather than a league table to act on. Nothing here measures how any individual will respond behind the wheel.